期刊文献+

卡维地洛治疗46例充血性心力衰竭患者的疗效分析

暂未订购
导出
摘要 目的:观察卡维地洛治疗慢性充血性心力衰竭(CHF)患者的临床疗效。方法:46例CHF患者在接受常规利尿剂、血管紧张素转换酶抑制剂、洋地黄等治疗,病情基本稳定的基础上,给予卡维地洛治疗,从小剂量2.5~5mg,每日2次开始逐渐增加剂量,至最大可耐受剂量后作为维持量观察(预定目标剂量为40mg/13)治疗6个月,观察治疗前、后不同时间心率、血压、左室射血分数、左室舒张末期内径、左室收缩末期内径、心胸比及心功能变化。结果:与治疗前相比,卡维地洛对心力衰竭患者血压、心率影响较明显(P〈0.01),且均可耐受;左室射血分数增加,(P〈0.01);左室舒张末期内径、左室收缩末期内径、心胸比减少,(P〈0.05);心功能改善总有效率达91.3%。结论:在常规治疗的基础上,应用卡维地洛治疗CHF能明显改善心功能,不良反应少,耐受性好。
作者 王中凯
出处 《现代预防医学》 CAS 北大核心 2006年第8期1501-1501,1503,共2页 Modern Preventive Medicine
  • 相关文献

参考文献3

  • 1杨田,沈萍,赵仙先.卡维地洛药理作用的研究进展[J].心血管病学进展,2003,24(2):110-113. 被引量:50
  • 2Australia/New Zealand Heart Failure Research. Callaboratire group. Randomaizecl, placebo - controlled trial of Carvedild in patients with con-gestive heart failure due to ischamaic heart disease[J]. Lancet, 1997, 349: 375.
  • 3Packer M, Coats AJ, FowlerMB, et al. Effect of Carvedilol on Survival in severe chronic heart failure [J]. N engl J Med, 2001,344: 1651.

二级参考文献24

  • 1[11]Santos DJ, Moreno AJ. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228 [J]. Biochem Pharmacol ,2001,61 (2): 155-164.
  • 2[12]Noguchi N, Nishino K,Niki E. Antioxidant action of the antihypertensive drug,carvedilol, against lipid peroxidation [J]. Biochem Pharmacol, 2000, 59 ( 9 ):1069-1076.
  • 3[13]Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis :protective role of carvedilol [J]. J Am Coll Cardilo,2001 ,36( 7 ) :2081-2089.
  • 4[14]Romeo F,LiM D,Shi M ,et al. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells:modulation of Fas/Fsa ligand and caspase-3 pathway [ J ]. Cardiovasc Res, 2000,45 ( 3 ) :788-794.
  • 5[15]Cao F,Chen J,Lopez BL,et al. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model [ J ]. Eur J Pharmacol,2000,406( 1 ) :109-116.
  • 6[16]Wei S.Chow LT,Sanderson JE,et al. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction[J]. J Am Coll Cardiol.2000,36( 1 ) :276-281.
  • 7[17]Ohta Y, Watanabe K, Nakazawa M,et al. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart[ J ]. J Cardiovasc Pharmacol,2000,36 ( suppl 2 ) 19-23.
  • 8[18]Savitz SI, Erhardt JA, Anhtony JV, et al. The novel β-bolcker, carvedilol, provides neuroprotection in transient focal stroke[J]. J Cereb Blood Flow Metab,2000,20(8) :1197-1204.
  • 9[19]Karle CA, Kreye VA,Thomas D, et al. Antarrhythmic drug carvedilol inhibits HERG potassium channels [ J ]. Cardiovasc Res,2001,49 ( 2 ): 361-370.
  • 10[20]Takusagawa M, Komori S, Matsumura K, et al. The inhibitory effects of carvedilol against arhytmias induced by coronary by coronary reperfusion in aneothetized rats [J]. J Cardiovasc Pharmacol Ther, 2000, 5 ( 2 ): 105 - 112.

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部